JP2014515408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515408A5 JP2014515408A5 JP2014513795A JP2014513795A JP2014515408A5 JP 2014515408 A5 JP2014515408 A5 JP 2014515408A5 JP 2014513795 A JP2014513795 A JP 2014513795A JP 2014513795 A JP2014513795 A JP 2014513795A JP 2014515408 A5 JP2014515408 A5 JP 2014515408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- bipolar disorder
- inositol
- scyllo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 208000020925 Bipolar disease Diseases 0.000 claims 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 206010026749 Mania Diseases 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- 229960000367 inositol Drugs 0.000 claims 4
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 206010021030 Hypomania Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 229960000604 valproic acid Drugs 0.000 claims 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 229940084026 sodium valproate Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520031P | 2011-06-03 | 2011-06-03 | |
| US61/520,031 | 2011-06-03 | ||
| US201161541333P | 2011-09-30 | 2011-09-30 | |
| US61/541,333 | 2011-09-30 | ||
| US201261618680P | 2012-03-31 | 2012-03-31 | |
| US61/618,680 | 2012-03-31 | ||
| PCT/US2012/040789 WO2012173808A1 (en) | 2011-06-03 | 2012-06-04 | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515408A JP2014515408A (ja) | 2014-06-30 |
| JP2014515408A5 true JP2014515408A5 (enExample) | 2015-07-23 |
Family
ID=46298680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513795A Pending JP2014515408A (ja) | 2011-06-03 | 2012-06-04 | 行動及び精神障害の治療のためのシロ−イノシトール |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140243422A1 (enExample) |
| EP (1) | EP2714050A1 (enExample) |
| JP (1) | JP2014515408A (enExample) |
| KR (1) | KR20140041670A (enExample) |
| CN (1) | CN103906520A (enExample) |
| AU (1) | AU2012271068A1 (enExample) |
| BR (1) | BR112013031117A8 (enExample) |
| CA (1) | CA2837926A1 (enExample) |
| IL (1) | IL229658A0 (enExample) |
| RU (1) | RU2013154699A (enExample) |
| WO (1) | WO2012173808A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2014110234A1 (en) * | 2013-01-09 | 2014-07-17 | Elan Pharmaceuticals, Llc | Methods of treating developmental and personality disorders |
| US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
| US20170000809A1 (en) * | 2015-06-30 | 2017-01-05 | Jds Therapeutics, Llc | Arginine silicate inositol for improving cognitive function |
| WO2017029353A1 (en) * | 2015-08-20 | 2017-02-23 | Transition Therapeutics Ireland Limited | Treatment of behaviors in dementia patients |
| US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
| GB2568849B (en) | 2016-09-01 | 2022-08-10 | Nutrition 21 Llc | Magnesium biotinate compositions and methods of use |
| CN113329680A (zh) | 2018-11-02 | 2021-08-31 | 营养21有限责任公司 | 用于改善视频游戏者认知功能的含有肌醇稳定的精氨酸硅酸盐复合物和肌醇的组合物 |
| HRP20250882T1 (hr) * | 2019-12-02 | 2025-09-26 | Suven Life Sciences Limited | Kombinacije masupirdina sa donepezilom ili memantinom za liječenje bihevioralnih i psiholoških simptoma kod pacijenata sa demencijom |
| BR112022010493A2 (pt) * | 2019-12-02 | 2022-09-06 | Suven Life Sciences Ltd | Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência |
| GB2613672A (en) | 2019-12-16 | 2023-06-14 | Nutrition 21 Llc | Methods of production of aginine-silicate complexes |
| EP4583851A1 (en) * | 2022-09-07 | 2025-07-16 | EirGen Pharma Ltd. | Scyllo-inositol in combination with immunotherapeutics for the treatment of alzheimer's disease |
| CN115998724B (zh) * | 2023-03-28 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 布洛芬在抗幻觉作用药物中的新用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| IL156203A0 (en) * | 2003-05-29 | 2003-12-23 | Yissum Res Dev Co | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| CA2774930C (en) | 2003-10-14 | 2014-08-05 | Hokko Chemical Industry Co., Ltd. | Method for producing purified scyllo-inositol utilizing boric acid |
| CN101505741A (zh) * | 2006-03-09 | 2009-08-12 | 瓦拉塔药品公司 | 用于治疗蛋白积聚病症的环己烷多元醇制剂 |
| WO2007101353A1 (en) * | 2006-03-09 | 2007-09-13 | Waratah Pharmaceuticals Inc. | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| US20110201060A1 (en) | 2010-02-15 | 2011-08-18 | Abbott Laboratories | Process for the preparation of scyllo-inositol |
| US20150306043A1 (en) * | 2012-09-28 | 2015-10-29 | Transition Therapeutics Ireland Limited | Combination treatments for bipolar disorders |
-
2012
- 2012-06-04 EP EP12727719.2A patent/EP2714050A1/en not_active Withdrawn
- 2012-06-04 CA CA2837926A patent/CA2837926A1/en not_active Abandoned
- 2012-06-04 AU AU2012271068A patent/AU2012271068A1/en not_active Abandoned
- 2012-06-04 KR KR1020147000006A patent/KR20140041670A/ko not_active Withdrawn
- 2012-06-04 RU RU2013154699/15A patent/RU2013154699A/ru not_active Application Discontinuation
- 2012-06-04 US US14/123,581 patent/US20140243422A1/en not_active Abandoned
- 2012-06-04 WO PCT/US2012/040789 patent/WO2012173808A1/en not_active Ceased
- 2012-06-04 BR BR112013031117A patent/BR112013031117A8/pt not_active IP Right Cessation
- 2012-06-04 CN CN201280037339.8A patent/CN103906520A/zh active Pending
- 2012-06-04 JP JP2014513795A patent/JP2014515408A/ja active Pending
-
2013
- 2013-11-27 IL IL229658A patent/IL229658A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| WO2015037248A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| JP2017510607A5 (enExample) | ||
| JP2020500875A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2012524112A5 (enExample) | ||
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| JP2010513250A5 (enExample) | ||
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| MX390101B (es) | Tratamiento medico que comprende administracion enteral de edaravona | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| BR112014004339A2 (pt) | suspensão oral | |
| RS59496B1 (sr) | Farmaceutska kompozicija za upotrebu u povećanju trofizma sluznice nosa | |
| JP2016504361A5 (enExample) | ||
| JP7335954B2 (ja) | 白頭翁サポニンｂ４の抗急性痛風性関節炎の医薬における用途 | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| JP2014530249A5 (enExample) | ||
| JP6100510B2 (ja) | 抗感冒剤 | |
| JP2013542262A5 (enExample) |